BioMedomics Secures NIH Grant for Sickle Cell Disease POC Test Development
BioMedomics, Inc. (RTP, NC) announces that the National Institutes of Health has awarded the company an SBIR Phase I grant for the development of a quantitative Point of Care (POC) test for hemoglobin S (HbS) and hemoglobin F (HbF). The $222,950 grant will be used to develop these POC tests to aid the treatment of the Sickle Cell Disease (SCD) patients. When available these tests will give clinicians immediate results of HbS and HbF which will improve treatment for these SCD patients. These new tests will be valuable synergistic additions to BioMedomics existing SickleScan and alpha-ThalScan screening tests which have already received CE Mark approval for SCD and alpha thalassemia.
SCD is one of the most common genetic disorders. In US alone, over 100,000 patients suffer from SCD which is a life threatening anemia focused mostly in the African American community. 50% of these patients undergo constant transfusions with the goal of lowering HbS. 30% of these patients receive chronic Hydroxyurea therapy with the goal of raising the patient’s HbF level. Quantitative levels of HbS or HbF are required to optimally manage these patients. Currently it takes several days to a week for clinicians to get these critical results back from central lab analytics. The NIH grant will assist BioMedomics in developing a POC quantitative test for HbS and HbF which will improve patient care by giving clinicians immediate results.
Dr. Frank Wang, CEO of BioMedomics, commented on the grant saying “We are very delighted to receive this NIH grant. The NIH review board has recognized our expertise in developing both qualitative and quantitative POC tests for significant hemoglobinopathies. This success was made possible by the hard work of our outstanding scientists and other staff members at BioMedomics. I am very proud of their achievements. These tests will be a great addition to our already approved SickleScan qualitative test for screening both Sickle Cell Disease and Sickle Trait patients.”
About BioMedomics, Inc. – BioMedomics is located in Research Triangle Park, NC and is developing advanced highly sensitive and quantitative rapid POC diagnostic platforms and novel disease specific diagnostic tests for the $16 billion POC diagnostic market. The company’s goal is to make POC testing widely accessible with the same level of sensitivity and quantitation as complex and expensive central lab tests. The core competencies of the company are a strong combination of biology, biochemistry, and biomedical engineering expertise that underline its technology and product development. The company’s initial focus has been on developing POC tests for hemoglobinopathies such as Sickle Cell Disease and thalassemias (alpha and beta). The second phase for the company will be to meet the increasing need for improved sensitivity in POC diagnostics by developing its next generation Time Resolved platform. The Company is developing tests for troponin, thyroid stimulating hormone (TSH) and testosterone utilizing its Time Resolved platform. To learn more about BioMedomics products and services, please contact firstname.lastname@example.org, or visit the website (biomedomics.com) for more details.
*Disclaimer: The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.